ITCI
Intra-Cellular Therapies Inc
A biopharmaceutical company making oral medicines for psychiatric and neurological conditions. Its signature drug, Caplyta, treats schizophrenia, bipolar depression, and major depression in adults. Founded in 2002 by Nobel Prize-winning neuroscientist Paul Greengard, the company is built on his research into how signals travel inside brain cells — the source of its "intra-cellular" name. Johnson & Johnson acquired it in 2025.
CUSIP: 46116X101HealthcareUS1 holder
Total Value
$24.0K
Total Shares
1.6K
Net Share Change
+1.6K
Activity
1 buying
Investor
Value
Shares
Weight
Change
